Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Non-Current Assets (2018 - 2025)

Quantum Biopharma's Non-Current Assets history spans 8 years, with the latest figure at $4.8 million for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 7.2% to $4.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $19.9 million, a 179.31% increase, with the full-year FY2023 number at $5.5 million, down 58.24% from a year prior.
  • Non-Current Assets hit $4.8 million in Q3 2025 for Quantum Biopharma, down from $5.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for QNTM hit a ceiling of $17.0 million in Q4 2021 and a floor of $4.8 million in Q3 2025.
  • Historically, Non-Current Assets has averaged $7.6 million across 5 years, with a median of $5.2 million in 2024.
  • Biggest five-year swings in Non-Current Assets: soared 163.39% in 2021 and later plummeted 58.24% in 2023.
  • Tracing QNTM's Non-Current Assets over 5 years: stood at $17.0 million in 2021, then fell by 22.91% to $13.1 million in 2022, then plummeted by 58.24% to $5.5 million in 2023, then fell by 5.45% to $5.2 million in 2024, then decreased by 7.2% to $4.8 million in 2025.
  • Business Quant data shows Non-Current Assets for QNTM at $4.8 million in Q3 2025, $5.0 million in Q2 2025, and $4.9 million in Q1 2025.